Stock Market & Financial Investment News

News For JNJ;AGN From The Last 14 Days Check below for free stories on JNJ;AGN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 09:04 EDT AGN Wells Faro to host a conference 2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link 08:36 EDT AGN Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. 07:34 EDT JNJ Medivation pullback a buying opportunity, says JPMorgan Subscribe for More Information 07:28 EDT AGN Wells Faro to host a conference Subscribe for More Information June 17, 2013 16:20 EDT JNJ On The Fly: Closing Wrap Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. 12:29 EDT JNJ On The Fly: Midday Wrap Subscribe for More Information 12:28 EDT JNJ Medivation retreats after J&J beefs up prostate cancer slate Subscribe for More Information 12:08 EDT JNJ J&J deal not negative for Medivation, says Citigroup Subscribe for More Information 08:04 EDT JNJ Johnson & Johnson agrees to acquire Aragon Pharmaceuticals Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. June 16, 2013 14:45 EDT JNJ J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says Subscribe for More Information June 14, 2013 15:49 EDT JNJ J&J's Mentor gets FDA approval for MemoryShape breast implants Mentor Worldwide announced earlier the U.S. Food and Drug Administration has approved MENTOR MemoryShape breast implants. The open-label, multi-center MENTOR MemoryShape Breast Implant Core Study showed the implants were safe and effective in both reconstruction and augmentation patients at 6 years, with a low rate of adverse events, such as rupture and capsular contracture Baker grades III and IV. Post approval studies will be conducted to collect additional clinical data for the MemoryShape implants. Mentor joined the Johnson & Johnson family of companies in 2009 and is part of its Global Surgery Group. June 13, 2013 17:39 EDT JNJ J&J files to sell 25.38M shares of Elan Subscribe for More Information 11:02 EDT JNJ Leerink's major pharma analyst holds an analyst/Industry conference call Subscribe for More Information 08:24 EDT JNJ J&J unit says data show Stelara improved components of psoriatic arthritis Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that results from a Phase 3 study published in The Lancet showed patients with active psoriatic arthritis who received either STELARA 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint compared with patients receiving placebo. According to findings from the investigational study, continued treatment with STELARA every 12 weeks resulted in improvements in signs and symptoms of active disease and psoriasis symptoms through one year. In December 2012, Janssen announced submissions to health authorities in the U.S. and Europe seeking approval of STELARA for the treatment of active psoriatic arthritis. STELARA is approved for the treatment of adults with moderate to severe plaque psoriasis in 72 countries. June 12, 2013 17:56 EDT JNJ Johnson & Johnson's Cordis receives FDA clearance for Adroit catheter Subscribe for More Information June 11, 2013 13:09 EDT AGN Allergan has a conference call hosted by BMO Capital Subscribe for More Information 10:56 EDT JNJ AstraZeneca to bid for Israeli biotech incubator, Globes reports Subscribe for More Information June 10, 2013 07:40 EDT JNJ Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:20 EDT JNJ Biomed to host a conference Subscribe for More Information June 5, 2013 09:28 EDT JNJ Second Genome announces agreement with Janssen Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.